Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Abstracts/special issue

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 08, 2023 2:08pm

37 Views

Post# 35326393

RE:Abstracts/special issue

I am sure these studies can help increase Egrifta sales slightly but I am not seeing a pathway to a new indication for Egrifta being established. A new indication may well be justified at some point but am I right in suggesting that will take a lot of time and money to perform the appropriate studies to get FDA approval?

scarlet1967 wrote:

Joint CDDW-CLM Conference 2023:

"Aging people with HIV (PWH) on antiretroviral therapy face high rates of metabolic dysfunction and nonalcoholic fatty liver disease (NAFLD). Fat alterations are frequent in PWH and predict worse cardiometabolic outcomes. Visceral adipose tissue (VAT) is an important compartment of body fat tissue releasing bioactive molecules. As a hormonally active tissue, VAT critically contributes to obesity-related disorders and is associated with ectopic fat accumulation in the liver."

A79 THE RELATIONSHIP BETWEEN VISCERAL ADIPOSITY AND NONALCOHOLIC FATTY LIVER DISEASE DIAGNOSED BY CONTROLLED ATTENUATION PARAMETER IN PEOPLE WITH HIV: A PILOT STUDY | Journal of the Canadian Association of Gastroenterology | Oxford Academic

CROI 2023:

"Background: Fat alterations are frequent in people with HIV (PWH) and predict worse cardiometabolic outcomes. Visceral adipose tissue (VAT) is a hormonally active tissue critically contributing to obesity-related disorders and associated with ectopic fat accumulation in the liver. We aimed to investigate HIV-associated nonalcoholic fatty liver disease (NAFLD) diagnosed by controlled attenuation parameter (CAP) as a marker of visceral adiposity."

CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD

Below was an open invitation for submission of studies related to adipose tissue's role in metabolic syndrome/obesity. Again point is the science will keep evolving and lately there is a significant amount of evidence,impact and interest regarding the adipose tissue and its effects on metabolic health specifically the metabolic active fat deep inside the body, around and inside the organs.

"The production of adipocyte-derived factors changes under different nutritional and pathological conditions that contribute to the pathophysiology of several comorbidities. This Special Issue focuses on metabolic changes and novel molecular pathways observed in obesity with a high emphasis on adipose tissues that can be targeted in the fight against obesity and metabolic syndrome."